New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: Findings from prospective cohort

Mengyi Zheng; Xi Wang; Yu Yin; Shuohua Chen; Caixia Guo; Shouling Wu; Yu Yuan

doi:10.59717/j.xinn-med.2024.100064

The Innovation Medicine > 2024 Vol. 2 > No. 2 > 100064

Next Article Previous Article

REPORT Open Access

Cite PDF

New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: Findings from prospective cohort

1.
Department of Occupational and Environmental Health, Key Laboratory of Environment and Health, Ministry of Education and State Key Laboratory of Environmental Health (Incubating), Huazhong University of Science and Technology, Wuhan 430030, China
2.
Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
3.
Health Department of Kailuan Group, Tangshan 063000, China
4.
Department of Cardiology, Kailuan General Hospital, Tangshan 063000, China
5.
These authors contributed equally

More Information

Corresponding authors: drwusl@163.com (S.W.); yuanyu8@hust.edu.cn (Y.Y.)
Received Date: 23 August 2023

Accepted Date: 06 February 2024

Published Online: 09 April 2024

The Innovation Medicine 2(2), https://doi.org/10.59717/j.xinn-med.2024.100064 | Cite this article

GRAPHICAL ABSTRACT

GRAPHICAL ABSTRACT

PUBLIC SUMMARY

PUBLIC SUMMARY
1. Onset age of metabolic-associated fatty liver disease (MAFLD) is a key factor of cardiovascular diseases (CVD).
  
  The incident CVD risks are the highest in the MAFLD patients who were diagnosed at a young age (<45 years).
  
  The risks gradually declined with each decade increase in MAFLD onset age in Chinese community-based cohort.
  
  The intensive prevention strategies of CVD and adequate therapy in young MAFLD patients are highlighted.

ABSTRACT

ABSTRACT

Whether the early-onset metabolic-associated fatty liver disease (MAFLD) would promote the development of cardiovascular disease (CVD) remains unknown. To investigate the association between MAFLD and the risks of incident CVD across different new-onset age groups, we included 67,160 participants free of MAFLD and CVD at baseline (2006-2007) from the Kailuan study. During the follow-up from baseline to December 31, 2015, 24,772 new-onset MAFLD cases were identified. Each new-onset MAFLD case was matched by one control subject randomly (age ± 1 year, sex-matched). Then 24,772 case-controls were followed up for CVD events. The end of follow-up was the first occurrence of a CVD event, the loss of the follow-up date, or the end of the follow-up (December 31, 2019). Cox proportional hazard regression models with age as the time scale were used to evaluate the hazard ratios (HRs) of incident CVD. During an average follow-up of 8.27 years, 2,881 cases of CVD were identified. After multivariate adjustment, the CVD risk gradually declined with each decade of increase in the MAFLD onset age. MAFLD cases younger than 45 years had the highest CVD risk (hazard ratio, HR, 2.64 [1.87-3.72]), while the CVD risk was attenuated in the 45 to 54 years (HR, 1.41, [1.21-1.65]). However, the HRs in two groups older than 55 years were not statistically significant (HR, 1.10 [0.96-1.25] and 1.05 [0.91-1.22]). Therefore, the onset age of MAFLD is an important predictor of CVD risk. Our finding highlights the importance of intensive prevention, screening, and management of CVD risk among individuals with early-onset MAFLD (diagnosis at <45 years).
- XXX

FullText(HTML)

REFERENCES

[1]	Eslam, M., Sanyal, A.J., and George, J. (2020). MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158: 1999−2014.e1991. DOI: 10.1053/j.gastro.2019.11.312. View in Article CrossRef Google Scholar
[2]	Eslam, M., Newsome, P.N., Sarin, S.K., et al. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73: 202−209. DOI: 10.1016/j.jhep.2020.03.039. View in Article CrossRef Google Scholar
[3]	Shiha, G., Korenjak, M., Eskridge, W., et al. (2021). Redefining fatty liver disease: An international patient perspective. Lancet Gastroenterol. Hepatol. 6: 73−79. DOI: 10.1016/S2468-1253(20)30294-6. View in Article CrossRef Google Scholar
[4]	Eslam, M., Sarin, S.K., Wong, V.W., et al. (2020). The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 14: 889−919. DOI: 10.1007/s12072-020-10094-2. View in Article CrossRef Google Scholar
[5]	Eslam, M., and George, J. (2021). MAFLD: A game changer redefining fatty liver disease for adults and children. J. Hepatol. 74: 992−994. DOI: 10.1016/j.jhep.2021.01.004. View in Article CrossRef Google Scholar
[6]	Spearman, C.W., Desalegn, H., Ocama, P., et al. (2021). The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. J. Hepatol. 74: 1256−1258. DOI: 10.1016/j.jhep.2021.01.015. View in Article CrossRef Google Scholar
[7]	Mendez, S.N., Arrese, M., Gadano, A., et al. (2021). The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol. Hepatol. 6: 65−72. DOI: 10.1016/S2468-1253(20)30340-X. View in Article CrossRef Google Scholar
[8]	Liu, J., Ayada, I., Zhang, X., et al. (2022). Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin. Gastroenterol. Hepatol. 20: e573−e582. DOI: 10.1016/j.cgh.2021.02.030. View in Article CrossRef Google Scholar
[9]	Lim, S., Kim, J.W., and Targher, G. (2021). Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol. Metab. 32: 500−514. DOI: 10.1016/j.tem.2021.04.008. View in Article CrossRef Google Scholar
[10]	Doycheva, I., Watt, K.D., and Alkhouri, N. (2017). Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology 65: 2100−2109. DOI: 10.1002/hep.29068. View in Article CrossRef Google Scholar
[11]	Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020). Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J. Am. Coll. Cardiol. 76: 2982−3021. DOI: 10.1016/j.jacc.2020.11.010. View in Article CrossRef Google Scholar
[12]	GBD 2017 DALYs and HALE Collaborators. (2018). Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 392 : 1859-1922. DOI: 10.1016/s0140-6736(18)32335-3. View in Article Google Scholar
[13]	Andersson, C., and Vasan, R.S. (2018). Epidemiology of cardiovascular disease in young individuals. Nat. Rev. Cardiol. 15: 230−240. DOI: 10.1038/nrcardio.2017.154. View in Article CrossRef Google Scholar
[14]	Strong, J.P., Malcom, G.T., McMahan, C.A., et al. (1999). Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 281: 727−735. DOI: 10.1001/jama.281.8.727. View in Article CrossRef Google Scholar
[15]	Piepoli, M.F., Hoes, A.W., Agewall, S., et al. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 37: 2315−2381. DOI: 10.1093/eurheartj/ehw106. View in Article CrossRef Google Scholar
[16]	Murthy, V.L., Reis, J.P., Pico, A.R., et al. (2020). Comprehensive metabolic phenotyping refines cardiovascular risk in young adults. Circulation 142: 2110−2127. DOI: 10.1161/circulationaha.120.047689. View in Article CrossRef Google Scholar
[17]	Gooding, H.C., Ning, H., Gillman, M.W., et al. (2017). Application of a lifestyle-based tool to estimate premature cardiovascular disease events in young adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Intern. Med. 177: 1354−1360. DOI: 10.1001/jamainternmed.2017.2922. View in Article CrossRef Google Scholar
[18]	Gidding, S.S., and Robinson, J. (2019). It is now time to focus on risk before age 40. J. Am. Coll. Cardiol. 74: 342−345. DOI: 10.1016/j.jacc.2019.04.064. View in Article CrossRef Google Scholar
[19]	Wang, C., Yuan, Y., Zheng, M., et al. (2020). Association of age of onset of hypertension with cardiovascular diseases and mortality. J. Am. Coll. Cardiol. 75: 2921−2930. DOI: 10.1016/j.jacc.2020.04.038. View in Article CrossRef Google Scholar
[20]	Sattar, N., Rawshani, A., Franzén, S., et al. (2019). Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation 139: 2228−2237. DOI: 10.1161/circulationaha.118.037885. View in Article CrossRef Google Scholar
[21]	Zhao, M., Song, L., Sun, L., et al. (2021). Associations of type 2 diabetes onset age with cardiovascular disease and mortality: The kailuan study. Diabetes Care 44: 1426−1432. DOI: 10.2337/dc20-2375. View in Article CrossRef Google Scholar
[22]	Rawshani, A., Sattar, N., Franzén, S., et al. (2018). Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 392: 477−486. DOI: 10.1016/s0140-6736(18)31506-x. View in Article CrossRef Google Scholar
[23]	Li, L., Zhao, M., Wang, C., et al. (2021). Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk. Clin. Res. Cardiol. 110: 1096−1105. DOI: 10.1007/s00392-021-01849-4. View in Article CrossRef Google Scholar
[24]	Huang, Z., Wang, X., Ding, X., et al. (2022). Association of age of metabolic syndrome onset with cardiovascular diseases: The kailuan study. Front. Endocrinol. 13: 857985. DOI: 10.3389/fendo.2022.857985. View in Article CrossRef Google Scholar
[25]	Armandi, A., and Bugianesi, E. (2023). Extrahepatic outcomes of nonalcoholic fatty liver disease: Cardiovascular diseases. Clin. Liver Dis. 27: 239−250. DOI: 10.1016/j.cld.2023.01.018. View in Article CrossRef Google Scholar
[26]	Wu, Z., Jin, C., Vaidya, A., et al. (2016). Longitudinal patterns of blood pressure, incident cardiovascular events, and all-cause mortality in normotensive diabetic people. Hypertension 68: 71−77. DOI: 10.1161/hypertensionaha.116.07381. View in Article CrossRef Google Scholar
[27]	Jin, C., Chen, S., Vaidya, A., et al. (2017). Longitudinal change in fasting blood glucose and myocardial infarction risk in a population without diabetes. Diabetes Care 40: 1565−1572. DOI: 10.2337/dc17-0610. View in Article CrossRef Google Scholar
[28]	Li, W., Jin, C., Vaidya, A., et al. (2017). Blood pressure trajectories and the risk of intracerebral hemorrhage and cerebral infarction: A prospective study. Hypertension 70: 508−514. DOI: 10.1161/HYPERTENSIONAHA.117.09479. View in Article CrossRef Google Scholar
[29]	Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., et al. (1994). Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 : 583-612. DOI: 10.1161/01.cir.90.1.583. View in Article Google Scholar
[30]	Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. (2018). Fourth universal definition of myocardial infarction (2018). Circulation 138: e618−e651. DOI: 10.1161/cir.0000000000000617. View in Article CrossRef Google Scholar
[31]	WHO. (1989). Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 20 : 1407-1431. DOI: 10.1161/01.str.20.10.1407. View in Article Google Scholar
[32]	Wang, Z.Y., Chen, S.H., Zhao, X.Y., et al. (2020). Application of Cox and extended regression models on modeling the effect of time-updated exposures in cohort studies. Zhonghua liu xing bing xue za zhi 41: 957−961. DOI: 10.3760/cma.j.cn112338-20200119-00046. View in Article CrossRef Google Scholar
[33]	Canchola, A.J., Stewart, S.L., Bernstein, L., et al. (2003). 1 COX REGRESSION USING DIFFERENT TIME-SCALES. Western Users of SAS Software. San Francisco, California. https://www.lexjansen.com/wuss/2003/DataAnalysis/i-cox_time_scales.pdf. View in Article Google Scholar
[34]	Schemper, M., Wakounig, S., and Heinze, G. (2009). The estimation of average hazard ratios by weighted Cox regression. Stat. Med. 28: 2473−2489. DOI: 10.1002/sim.3623. View in Article CrossRef Google Scholar
[35]	Mantovani, A., Csermely, A., Petracca, G., et al. (2021). Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6: 903−913. DOI: 10.1016/S2468-1253(21)00308-3. View in Article CrossRef Google Scholar
[36]	Targher, G., Byrne, C.D., Lonardo, A., et al. (2016). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J. Hepatol. 65: 589−600. DOI: 10.1016/j.jhep.2016.05.013. View in Article CrossRef Google Scholar
[37]	Lee, H., Lee, Y.H., Kim, S.U., et al. (2021). Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study. Clin. Gastroenterol. Hepatol. 19: 2138−2147.e2110. DOI: 10.1016/j.cgh.2020.12.022. View in Article CrossRef Google Scholar
[38]	Guerreiro, G.T.S., Longo, L., Fonseca, M.A., et al. (2021). Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD. Hepatol. Int. 15: 380−391. DOI: 10.1007/s12072-021-10157-y. View in Article CrossRef Google Scholar
[39]	Lim, G.E.H., Tang, A., Ng, C.H., et al. (2021). An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin. Gastroenterol. Hepatol. 21: 619−629. DOI: 10.1016/j.cgh.2021.11.038. View in Article CrossRef Google Scholar
[40]	Roth, G.A., Mensah, G.A., and Fuster, V. (2020). The global burden of cardiovascular diseases and risks: A compass for global action. J. Am. Coll. Cardiol. 76: 2980−2981. DOI: 10.1016/j.jacc.2020.11.021. View in Article CrossRef Google Scholar
[41]	Zhou, X.D., Targher, G., Byrne, C.D., et al. (2023). An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol. Int. 17: 773−791. DOI: 10.1007/s12072-023-10543-8. View in Article CrossRef Google Scholar
[42]	Goh, G.B., Pagadala, M.R., Dasarathy, J., et al. (2015). Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 35: 979−985. DOI: 10.1111/liv.12611. View in Article CrossRef Google Scholar
[43]	Chew, N.W.S., Chong, B., Ng, C.H., et al. (2022). The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front. Genet. 13: 971484. DOI: 10.3389/fgene.2022.971484. View in Article CrossRef Google Scholar
[44]	Simons, N., Isaacs, A., Koek, G.H., et al. (2017). PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease. Gastroenterology 152: 912−913. DOI: 10.1053/j.gastro.2016.12.020. View in Article CrossRef Google Scholar
[45]	Albillos, A., de Gottardi, A., and Rescigno, M. (2020). The gut-liver axis in liver disease: Pathophysiological basis for therapy. J. Hepatol. 72: 558−577. DOI: 10.1016/j.jhep.2019.10.003. View in Article CrossRef Google Scholar
[46]	Hu, H., Lin, A., Kong, M., et al. (2020). Intestinal microbiome and NAFLD: Molecular insights and therapeutic perspectives. J. Gastroenterol. 55: 142−158. DOI: 10.1007/s00535-019-01649-8. View in Article CrossRef Google Scholar
[47]	Bucholz, E.M., Gooding, H.C., and de Ferranti, S.D. (2018). Awareness of cardiovascular risk factors in U.S. young adults aged 18-39 years. Am. J. Prev. Med. 54 : e67-e77. DOI: 10.1016/j.amepre.2018.01.022. View in Article Google Scholar
[48]	European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64: 1388−1402. DOI: 10.1016/j.jhep.2015.11.004. View in Article CrossRef Google Scholar
[49]	Castera, L., Friedrich-Rust, M., and Loomba, R. (2019). Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156: 1264−1281.e1264. DOI: 10.1053/j.gastro.2018.12.036. View in Article CrossRef Google Scholar
[50]	Hernaez, R., Lazo, M., Bonekamp, S., et al. (2011). Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 54: 1082−1090. DOI: 10.1002/hep.24452. View in Article CrossRef Google Scholar
[51]	Lazarus, J.V., Mark, H.E., Anstee, Q.M., et al. (2022). Advancing the global public health agenda for NAFLD: A consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19: 60−78. DOI: 10.1038/s41575-021-00523-4. View in Article CrossRef Google Scholar

CITED BY

ABOUT THIS ARTICLE

Cite this article:

Zheng M., Wang X., Yin Y., et al., (2024). New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: Findings from prospective cohort. The Innovation Medicine 2(2): 100064. https://doi.org/10.59717/j.xinn-med.2024.100064

Zheng M., Wang X., Yin Y., et al., (2024). New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: Findings from prospective cohort. The Innovation Medicine 2(2): 100064. https://doi.org/10.59717/j.xinn-med.2024.100064

Standard PDF

Extended PDF

Figures(2) Tables(1)

Article Metrics

Article views(2569) PDF downloads(753) Cited by(0)

Relative Articles

Article Contents

ABOUT THIS ARTICLE

New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: Findings from prospective cohort

GRAPHICAL ABSTRACT

PUBLIC SUMMARY

ABSTRACT

REFERENCES

ABOUT THIS ARTICLE

Cite this article:

Share

Article Metrics

Relative Articles

Catalog

{{newsColumn.name}}

Journal links

{{newsColumn.name}}

Stay connected

New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: Findings from prospective cohort

GRAPHICAL ABSTRACT

PUBLIC SUMMARY

ABSTRACT

REFERENCES

ABOUT THIS ARTICLE

Cite this article:

Share

Article Metrics

Relative Articles

Catalog

Export File

Citation

Format

Content

{{newsColumn.name}}

Journal links

{{newsColumn.name}}

Stay connected